Age of Postmenopause Women: Effect of Soy Isoflavone in Lipoprotein and Inflammation Markers

키워드

참고문헌 (35)

1. Mendelsohn ME, "Molecular and cellular basis of cardiovascular gender differences", Science, 308, pp.1583~1587 (2005)
2. Cui J, "Estrogen synthesis and signaling pathways during aging : from periphery to brain", Trends Mol Med, 19, pp.197~209 (2013)
3. Chahal HS, "The endocrine system and ageing", J Pathol, 211, pp.173~180 (2007)
4. Manson JE, "Estrogen plus progestin and the risk of coronary heart disease", N Engl J Med, 349, pp.523~534 (2003)
5. Hulley S, "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women", JAMA, 280, pp.605~613 (1998), Heart and Estrogen[DOI]
6. Cano A, "Isoflavones and cardiovascular disease", Maturitas, 67, pp.219~226 (2010)
7. Bertonazzi A, "The smallest available estradiol transdermal patch : a new treatment option for the prevention of postmenopausal osteoporosis", Womens Health (Lond), 11, pp.815~824 (2015)
8. Munro IC, "Soy isoflavones: a safety review", Nutr Rev, 61, pp.1~33 (2003)
9. Vitale DC, "Isoflavones:estrogenic activity, biological effect and bioavailability", Eur J Drug Metab Pharmacokinet, 38, pp.15~25 (2013)
10. An J, "Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoes trogens", J Biol Chem, 276, pp.17808~17814 (2001)
11. Messina M., "Soy and health update: Evaluation of the clinical and epidemiologic literature", Nutrients, 8, pp.E754~ (2016)
12. Taku K, "Soy isoflavones lower serum total and LDL cholesterol in humans : a meta-analysis of 11 randomized controlled trials", Am J Clin Nutr, 85, pp.1148~1156 (2007)
13. Fujimoto TT, "Expression and functional characterization of the P-selectin glycoprotein ligand-1 in various cells", Int J Hematol, 64, pp.231~239 (1996)
14. Myers DD, "P-selectin and leukocyte microparticles are associated with venous thrombogenesis", J Vasc Surg, 38, pp.1075~1089 (2003)
15. André P, "Pro-coagulant state resulting from high levels of soluble P-selectin in blood", Proc Natl Acad Sci U S A, 97, pp.13835~13840 (2000)
16. Mach F, "Activation of monocyte", macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor, 1997, pp.96, 396~399
17. Lindmark E, "Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression", Arterioscler Thromb Vasc Biol, 20, pp.2322~2328 (2000)
18. Friedewald WT, "Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge", Clin Chem, 18, pp.499~502 (1972)
19. Allanore Y, "Increased plasma soluble CD40 ligand concentrations in systemic sclerosis and association with pulmonary arterial hypertension and digital ulcers", Ann Rheum Dis, 64, pp.481~483 (2005)
20. Miller VT, "Effects of estrogen or estrogen", progestin regimens on heart disease risk factors in postmenopausal women, 1995, pp.273, 199~208[DOI]
21. Alwers R, "Changes in normal lipid profile of menopausal women with combined hormone replacement therapy. Comparative clinical trial of two hormonal combinations (conjugated estrogens", medroxyprogesterone acetate versus estradiol valerate, Maturitas, pp.1999, 32[DOI]
22. Harman SM, "Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes", Am J Med, 124, pp.199~205 (2011)
23. Hodis HN, "Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis", Menopause, 22, pp.391~401 (2015)
24. Kuiper GG, "Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta", Endocrinology, 139, pp.4252~4263 (1998)
25. Oseni T, "Selective estrogen receptor modulators and phytoestrogens", Planta Med, 74, pp.1656~1665 (2008)
26. Li J, "Does genistein lower plasma lipids and homocysteine levels in postmenopausal women? A meta-analysis", Climacteric, 19, pp.440~447 (2016)
27. Mangano KM, "Soy proteins and isoflavones reduce interleukin-6 but not serum lipids in older women : a randomized controlled trial", Nutr Res, 33, pp.1026~1033 (2013)
28. Simental-Mendia LE, "Effect of soy isoflavone supplementation on plasma lipoprotein(a)concentrations : A metaanalysis", J Clin Lpiidol, 12, pp.16~24 (2018)
29. Nagasawa M, "Analysis of serum soluble CD40 ligand(sCD40L)in the patients undergoing allogeneic stem cell transplantation : platelet is a major source of serum sCD40L", Eur J Haematol, 74, pp.54~60 (2005)
30. Gerdes N, "Platelet CD40 exacerbates atherosclerosis by transcellular activation of endothelial cells and leukocytes", Arterioscler Thromb Vasc Biol, 36, pp.482~490 (2016)
31. Gresele P, "Inhibitors of the interaction between von Willebrand factor and platelet GPIb", IX, Handb Exp Pharmacol, pp.2012[DOI]
32. Enomoto Y, "Thromboxane A(2)promotes soluble CD40 ligand release from human platelets", Atherosclerosis, 209, pp.415~421 (2010)
33. Guerrero JA, "Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor", J Thromb Haemost, 3, pp.369~376 (2005)
34. Muñoz Y, "Equol is more active than soy isoflavone itself to compete for binding to throm MM boxane A(2) receptor in human platelets", Thromb Res, 123, pp.740~744 (2009)
35. Gonzalez N, "In vitro effect of soy isoflavone and equol on soluble CD40L release stimulated by ristocetin in platelets from postmenopause women", JBiSE, 8, pp.24~30 (2015)

관련 논문AI추천